Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications

참고문헌 (115)

1. Yang, Z., "Nanotechnology platforms for cancer immunotherapy", Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol, 12, pp.e1590~ (2020)
2. Yang, Y. P., "Cancer immunotherapy : harnessing the immune system to battle cancer", J. Clin. Investig, 125, pp.3335~3337 (2015)
3. Dunkelberger, J. R., "Complement and its role in innate and adaptive immune responses", Cell Res, 20, pp.34~50 (2010)
4. Yan, W., "Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle", Trends Cancer, 6, pp.506~517 (2020)
5. Zhang, H., "Exosomes as smart drug delivery vehicles for cancer immu notherapy", Front. Immunol, 13, pp.1093607~ (2023)
6. Dobosz, P., "The Intriguing History of Cancer Immunotherapy", Front. Immunol, 10, pp.2965~ (2019)
7. Wang, D. R., "Therapeutic targets and biomarkers of tumor immunotherapy : response versus non-response", Signal Transduct. Target Ther, 7, pp.331~ (2022)
8. Kim, H. D., "Immunological and clinical implications of immune checkpoint blockade in human cancer", Arch. Pharm. Res, 42, pp.567~581 (2019)
9. Zhao, Z., "The application of CAR-T cell therapy in hematological malignancies: advantages and challenges", Acta Pharm. Sin. B, 8, pp.539~551 (2018)
10. Xu, Z., "Exosome-based immunotherapy : a promising approach for cancer treatment", Mol. Cancer, 19, pp.160~ (2020)
11. S, E. L. A., "Extracellular vesicles : biology and emerging therapeutic opportunities", Nat. Rev. Drug Discov, 12, pp.347~357 (2013)
12. Samanta, S., "Exosomes : new molecular targets of diseases", Acta Pharm. Sin, 39, pp.501~513 (2018)
13. Choi, S. J., "Immune cell-derived small extracellular vesicles in cancer treatment", BMB Rep, 55, pp.48~56 (2022)
14. Veerman, R. E., "Immune Cell Derived Extracellular Vesicles- Functions and Therapeutic Applications", Trends Mol. Med, 25, pp.382~394 (2019)
15. Zhao, Y., "Immune-Cell-Derived Exosomes for Cancer Therapy", Mol. Pharm, 19, pp.3042~3056 (2022)
16. Markov, O., "Immunotherapy Based on Dendritic Cell-Targeted", -Derived Extracellular Vesicles-A Novel Strategy for Enhancement of the Anti-tumor Immune Response, 2019, pp.10, 1152~
17. Liang, Y., "Engineering exosomes for targeted drug delivery", Theranostics, 11, pp.3183~3195 (2021)
18. Yang, P. X., "Immune Cell-Derived Extracellular Vesicles-New Strategies in Cancer Immunotherapy", Front. Immunol, 12, pp.771551~ (2021)
19. Luan, X., "Engineering exosomes as refined biological nanoplatforms for drug delivery", Acta Pharmacol. Sin, 38, pp.754~763 (2017)
20. Sen, S., "Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives", 3 Biotech, 13, pp.101~ (2023)
21. Noh, S., "Exploring Membrane-tethering Technology for Proteins as a Ver satile Tool for Uncovering Novel Disease Targets and Advancing Biotherapeutic Development", Isr. J. Chem, pp.e202300046~ (2023)
22. Besse, B., "Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC", Oncoimmunology, 5, pp.e1071008~ (2016)
23. Cheng, L. F., "Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenviron ment in the Lymph Node", Mol. Ther, 25, pp.1665~1675 (2017)
24. Enomoto, Y., "Cytokine-enhanced cytolytic activity of exosomes from NK Cells", Cancer Gene Ther, 29, pp.734~749 (2022)
25. Shin, S., "Novel antitumor therapeutic strategy using CD4(+)T cell-derived extracellular vesicles", Biomaterials, 289, pp.121765~ (2022)
26. Li, L., "IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8(+)T cells", Sci. Rep, 7, pp.13365~ (2017)
27. Lu, Y., "Engineering exosomes and biomaterial assisted exosomes as therapeutic carriers for bone regeneration", Stem Cell Res. Ther, 14, pp.55~ (2023)
28. Kaban, K., "Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer", Cancers, 13, pp.2397~ (2021)
29. Han, D., "Natural killer cell-derived exosome-entrapped paclitaxel can enhance its anti-tumor effect", Eur. Rev. Med. Pharmacol. Sci, 24, pp.5703~5713 (2020)
30. Wang, P. P., "Exosomes from M1-Polarized Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation", Ther anostics, 9, pp.1714~1727 (2019)
31. Johnson, V., "Surface-Engineered Extracellular Vesicles in Cancer Immunotherapy", Cancers, 15, pp.2838~ (2023)
32. Liu, C., "A nanovaccine for antigen self-presentation and immunosuppres sion reversal as a personalized cancer immunotherapy strategy", Nat. Nano technol, 17, pp.531~540 (2022)
33. Jung, D., "Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery", J. Extracell. Vesicles, 11, pp.e12287~ (2022)
34. Cho, H., "Engineered CD8(+)T cell-derived extracellular vesicles induce enhanced anti-cancer efficacy and targeting to lung cancer cells", Cytokine, 169, pp.156249~ (2023)
35. Algar, W. R., "The controlled display of biomolecules on nanoparticles : a challenge suited to bioorthogonal chemistry", Bioconjug Chem, 22, pp.825~858 (2011)
36. Nie, W., "Responsive Exosome Nano-bioconjugates for Synergistic Cancer Therapy", Angew. Chem. Int Ed. Engl, 59, pp.2018~2022 (2020)
37. Kim, M. S., "Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases : in vitro and in vivo evaluations", Nanomedicine, 14, pp.195~204 (2018)
38. Radford, K. J., "Dendritic cells and cancer immu notherapy", Curr. Opin. Immunol, 27, pp.26~32 (2014)
39. Sabado, R. L., "Cancer immunotherapy: dendritic-cell vaccines on the move", Nature, 519, pp.300~301 (2015)
40. Andre, F., "Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I", peptide complexes to dendritic cells, 2004, pp.172, 2126~2136
41. Zitvogel, L., "Eradication of established murine tumors using a novel cell free vaccine : dendritic cell-derived exosomes", Nat. Med, 4, pp.594~600 (1998)
42. Gao, W., "Dendritic cells derived exosomes migration to spleen and induction of inflammation are regulated by CCR7", Sci. Rep, 7, pp.1~9 (2017)
43. Lindenbergh, M. F. S., "Antigen Presentation by Extracellular Vesicles from Professional Antigen-Presenting Cells", Annu. Rev. Immunol, 36, pp.435~459 (2018)
44. Munich, S., "Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands", Oncoimmunology, 1, pp.1074~1083 (2012)
45. Viaud, S., "Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation : A Role for NKG2D Ligands and IL-15R alpha", Plos One, 4, pp.e4942~ (2009)
46. Segura, E., "ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming", Blood, 106, pp.216~223 (2005)
47. Montecalvo, A., "Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes", Blood, 119, pp.756~766 (2012)
48. Naslund, T., "Dendritic cell derived exosomes need to activate both T and B cells to induce antitumor immunity", J. Immunol, 190, pp.2712~2719 (2013)
49. Damo, M., "TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma", Sci. Rep, 5, pp.17622~ (2015)
50. Pitt, J. M., "Dendritic cell-derived exosomes for cancer therapy", J. Clin. Investig, 126, pp.1224~1232 (2016)
51. Lu, Z., "Dendritic cell-derived exosomes elicit tumor regression in auto chthonous hepatocellular carcinoma mouse models", J. Hepatol, 67, pp.739~748 (2017)
52. Zuo, B. F., "Universal immunotherapeutic strategy for hepatocellular carci noma with exosome vaccines that engage adaptive and innate immune responses", J. Hematol. Oncol, 15, pp.46~ (2022)
53. Fan, M., "A CAR T-inspiring platform based on antibody-engineered exo somes from antigen-feeding dendritic cells for precise solid tumor therapy", Biomaterials, 282, pp.121424~ (2022)
54. Jung, M., "Nanovesicle-Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects", Adv. Mater, 34, pp.2106516~ (2022)
55. Wu, K. R., "Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence", Sci. Adv, 9, pp.eade062~ (2023)
56. Myers, J. A., "Exploring the NK cell platform for cancer immu notherapy", Nat. Rev. Clin. Oncol, 18, pp.85~100 (2021)
57. Shimasaki, N., "NK cells for cancer immunotherapy", Nat. Rev. Drug Discov, 19, pp.200~218 (2020)
58. Kang, Y. T., "On-Chip Biogenesis of Circulating NK Cell-Derived Exosomes in Non Small Cell Lung Cancer Exhibits Antitumoral Activity", Adv. Sci, 8, pp.2003747~ (2021)
59. Jong, A. Y., "Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells", J. Extracell. Vesicles, 6, pp.1294368~ (2017)
60. Zhu, L., "Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma", Theranostics, 7, pp.2732~2745 (2017)
61. Zhu, L., "Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming", Biomaterials, 190-191, pp.38~50 (2019)
62. Aarsund, M., "Comparison of char acteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12", 15, Cancer Immunol. Immunother, pp.2022, 71[DOI]
63. Nie, W. D., "Natural killer cell-derived extracellular vesicle significantly enhanced adoptive T cell therapy against solid tumors via versatilely immu nomodulatory coordination", Sci. China-Chem, 64, pp.1999~2009 (2021)
64. Wang, G. S., "Cocktail Strategy Based on NK Cell-Derived Exosomes and Their Biomimetic Nanoparticles for Dual Tumor Therapy", Cancers, 11, pp.1560~ (2019)
65. Tomita, R., "Macrophage-derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT", GSK-3 beta pathway, 2020, pp.44, 1905~1916
66. Yuan, Y., "Macrophage-Derived Exosomal miR-31-5p Promotes Oral Squa mous Cell Carcinoma Tumourigenesis Through the Large Tumor Suppressor 2-Mediated Hippo Signalling Pathway", J. Biomed. Nanotechnol, 17, pp.822~837 (2021)
67. Wei, K., "M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942", Cancer Lett, 526, pp.205~216 (2022)
68. Ngambenjawong, C., "Progress in tumor-associated macrophage(TAM)-targeted therapeutics", Adv. Drug Deliv. Rev, 114, pp.206~221 (2017)
69. Bernsmeier, C., "Innate immune cells in cirrhosis", J. Hepatol, 73, pp.186~201 (2020)
70. Zhao, Y., "M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer", Pharmaceutics, 13, pp.1493~ (2021)
71. Qian, B., "M1 macrophage-derived exosomes impair beta cell insulin secretion via miR-212-5p by targeting SIRT2 and inhibiting Akt", GSK-3beta, Diabetologia, pp.2021, 64[DOI]
72. Meng, W., "Exosome-orchestrated hypoxic tumor microenvironment", Mol. Cancer, 18, pp.57~ (2019)
73. Choo, Y. W., "M1 Macrophage-Derived Nanovesicles Potentiate the Antic ancer Efficacy of Immune Checkpoint Inhibitors", ACS Nano, 12, pp.8977~8993 (2018)
74. Gunassekaran, G. R., "M1macrophage exosomes engineered to foster M1 polarization and target the IL-4receptor inhibit tumor growth by reprogramming tumor-associated macro phages into M1-like macrophages", Biomaterials, 278, pp.121137~ (2021)
75. Wang, S., "Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor micro environment", Sci. Transl. Med, 13, pp.eabb6981~ (2021)
76. Selders, G. S., "An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration", Regen. Biomater, 4, pp.55~68 (2017)
77. Summers, C., "Neutrophil kinetics in health and disease", Trends Immunol, 31, pp.318~324 (2010)
78. Wang, J., "Inflammatory tumor microenvironment responsive neutrophil exosome-based drug delivery system for targeted glioma therapy", Biomaterials, 273, pp.102784~ (2021)
79. Zhang, J., "Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy", Sci. Adv, 8, pp.eabj8207~ (2022)
80. Hong, C. W., "Extracellular Vesicles of Neutrophils", Immune Netw, 18, pp.e43~ (2018)
81. Hyun, Y. M., "Uropod elongation is a common final step in leukocyte extravasation through inflamed vessels", J. Exp. Med, 209, pp.1349~1362 (2012)
82. Youn, Y. J., "Neutrophil-derived trail is a proinflammatory subtype of neutrophil-derived extracellular vesicles", Theranostics, 11, pp.2770~2787 (2021)
83. Dalli, J., "Heterogeneity in neutrophil microparticles reveals distinct pro teome and functional properties", Mol. Cell Proteom, 12, pp.2205~2219 (2013)
84. Eken, C., "Polymorphonuclear neutrophil-derived ectosomes interfere with the maturation of monocyte-derived dendritic cells", J. Immunol, 180, pp.817~824 (2008)
85. Eken, C., "Ectosomes released by polymorphonuclear neutrophils induce a MerTK-dependent anti-inflammatory pathway in macrophages", J. Biol. Chem, 285, pp.39914~39921 (2010)
86. Pliyev, B. K., "Neutrophil microparticles modulate cytokine production by natural killer cells", Cytokine, 65, pp.126~129 (2014)
87. Wu, M., "MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma", Nat. Commun, 9, pp.4777~ (2018)
88. Palucka, A. K., "The Basis of Oncoimmunology", Cell, 164, pp.1233~1247 (2016)
89. Thommen, D. S., "T Cell Dysfunction in Cancer", Cancer Cell, 33, pp.547~562 (2018)
90. Helmink, B. A., "B cells and tertiary lymphoid structures promote immu notherapy response", Nature, 577, pp.549~555 (2020)
91. Satitsuksanoa, P., "B-cell responses in allergen immunotherapy", Curr. Opin. Allergy Clin. Immunol, 19, pp.632~639 (2019)
92. Chen, W., "Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells", Eur. J. Immunol, 36, pp.1598~1607 (2006)
93. Klinker, M. W., "Human B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand and Secrete MHCII(+)FasL(+)Killer Exosomes", Front. Immunol, 5, pp.144~ (2014)
94. Dumontel, B., "Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices", Cell Biosci, 12, pp.61~ (2022)
95. Hickey, J. W., "Adaptive Nanoparticle Platforms for High Throughput Expansion and Detection of Antigen-Specific T cells", Nano Lett, 20, pp.6289~6298 (2020)
96. Borst, J., "CD4(+)T cell help in cancer immunology and immunotherapy", Nat. Rev. Immunol, 18, pp.635~647 (2018)
97. Crotty, S., "A brief history of T cell help to B cells", Nat. Rev. Immunol, 15, pp.185~189 (2015)
98. Lu, J., "CD4(+)T Cell-Released Extracellular Vesicles Potentiate the Efficacy of the HBsAg Vaccine by Enhancing B Cell Responses", Adv. Sci, 6, pp.1802219~ (2019)
99. Notarbartolo, S., "Human T lymphocytes at tumor sites", Semin. Immunopathol, 44, pp.883~901 (2022)
100. Peters, P. J., "Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes", J. Exp. Med, 173, pp.1099~1109 (1991)
101. Seo, N., "Activated CD8(+)T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells", Nat. Commun, 9, pp.435~ (2018)
102. Wu, S. W., "CTL-Derived Exosomes Enhance the Acti vation of CTLs Stimulated by Low-Affinity Peptides", Front. Immunol, 10, pp.1274~ (2019)
103. Li, B. Q., "Engineered T cell extracellular vesicles displaying PD-1 boost anti tumor immunity", Nano Today, 46, pp.101606~ (2022)
104. Messmer, A. S., "CAR T-cell therapy and critical care : A survival guide for medical emergency teams", Wien. Klin. Wochenschr, 133, pp.1318~1325 (2021)
105. Yang, P., "The exosomes derived from CAR-T cell efficiently target meso thelin and reduce triple-negative breast cancer growth", Cell Immunol, 360, pp.104262~ (2021)
106. Fu, W. Y., "CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity", Nat. Commun, 10, pp.4355~ (2019)
107. Escudier, B., "Vaccination of metastatic melanoma patients with autologous dendritic cell(DC)derived-exosomes : results of thefirst phase I clinical trial", J. Transl. Med, 3, pp.10~ (2005)
108. Morse, M. A., "A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer", J. Transl. Med, 3, pp.9~ (2005)
109. Yamashita, T., "Possibility of Exosome-Based Ther apeutics and Challenges in Production of Exosomes Eligible for Therapeutic Application", Biol. Pharm. Bull, 41, pp.835~842 (2018)
110. Syromiatnikova, V., "Methods of the Large-Scale Production of Extracellular Vesicles", Int. J. Mol. Sci, 23, pp.10522~ (2022)
111. Lamparski, H. G., "Production and characterization of clinical grade exo somes derived from dendritic cells", J. Immunol. Methods, 270, pp.211~226 (2002)
112. Colao, I. L., "Manufacturing Exosomes: A Promising Therapeutic Platform", Trends Mol. Med, 24, pp.242~256 (2018)
113. Jeyaram, A., "Preservation and Storage Stability of Extracellular Vesicles for Therapeutic Applications", AAPS J, 20, pp.1~ (2017)
114. Komuro, H., "Advances of engineered extracellular vesicles-based therapeutics strategy", Sci. Technol. Adv. Mater, 23, pp.655~681 (2022)
115. Jafari, D., "Designer Exosomes : A New Platform for Biotechnology Ther apeutics", BioDrugs, 34, pp.567~586 (2020)

관련 논문AI추천